Table 4.
Results of serum hepatitis B virus surface antibody test in OBI patients.
| Group | Time | anti-HBs (+) | anti-HBs, (Q1, Q3), mIU/ml | |||
|---|---|---|---|---|---|---|
| n° (%) | ||||||
| ≥10 and <100 | ≥100 and <500 | ≥500 and <1000 | ≥1000 | |||
| mIU/ml | mIU/ml | mIU/ml | mIU/ml | |||
| Group A (n=44) | 0 w | 27 (61.36) | 10 (22.73) | 1 (2.27) | N | 42.47 (16.85,109.10) |
| 12 w | 6 (13.64) | 9 (20.45) | 2 (4.55) | 27 (61.36) | 1000 (230.4,1000)* | |
| 24 w | 4 (9.09) | 7 (15.91) | 5 (11.36) | 28 (63.64) | 1000 (485.1,1000)* | |
| 36 w | 4 (9.09) | 7 (15.91) | 4 (9.09) | 29 (65.91) | 1000 (483.9,1000)* | |
| Group B (n=39) | 0 w | 20 (51.28) | 12 (30.77) | N | N | 39.27 (16.06,117.40) |
| 12 w | 19 (48.72) | 13 (33.33) | N | N | 39.04 (16.09,112.60) | |
| 24 w | 20 (51.28) | 12 (30.77) | N | N | 40.48 (18.97,117.20) | |
| 36 w | 21 (53.85) | 11 (28.21) | N | N | 38.78 (16.18,115.20) | |
N, none; n°, number of cases; M, median; Q1, first quartile; Q3, third quartile; *, the difference was statistically significant compared with week 0 (P<0.05).